Based in Boston, Massachusetts, Organix’s services are dedicated to drug discovery and preclinical development. The company, which has approximately 47 employees and generates annual revenue of more than $10 million, broadens Symeres’ offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines.

“Organix is widely known as a highly innovative and expert organic chemistry services provider that solves complex projects for top tier clients globally,” said Eelco Ebbers, co-founder and CEO of Symeres. “Joining forces represents a fantastic opportunity for Symeres to expand our drug discovery capability offering and will provide an exceptional foothold into the US market.”

Symeres is majority owned by French investment group Keensight Capital, which bought its stake in May 2021 from specialist healthcare investor Gilde Healthcare.

Author: Elaine Burridge, Freelance Journalist